Drug Profile
Larotectinib companion diagnostic - Roche Tissue Diagnostics
Latest Information Update: 13 Jul 2021
Price :
$50
*
At a glance
- Originator Ventana Medical Systems
- Developer Loxo Oncology; Ventana Medical Systems
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
- 15 Feb 2019 Loxo Oncology has been acquired by Eli Lilly
- 13 Dec 2018 Discontinued for Cancer (Diagnosis) in USA (unspecified route) (Loxo oncology email communication, December 2018)